Farallon Capital Management’s Generation Bio GBIO Stock Holding History

Farallon Capital Management’s Portfolio GBIO Stock Details GBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-124,938	Closed	-$4.91M	–	199
2022 Q4	$4.91M	Sell	124,938 -125,062	-50%	-$6.57M	0.03%	146
2022 Q3	$13.3M	Sell	250,000 -39,730	-14%	-$2.49M	0.07%	118
2022 Q2	$19M	Sell	289,730 -60,270	-17%	-$3.94M	0.1%	100
2022 Q1	$25.7M	Hold	350,000	–	–	0.12%	89
2021 Q4	$24.8M	Hold	350,000	–	–	0.12%	84
2021 Q3	$87.7M	Hold	350,000	–	–	0.41%	57
2021 Q2	$94.2M	Buy	350,000 +22,950	+7%	+$6.87M	0.38%	56
2021 Q1	$93.1M	Buy	327,050 +100,168	+44%	+$32.1M	0.46%	52
2020 Q4	$64.3M	Buy	226,882 +14,819	+7%	+$4.76M	0.39%	59
2020 Q3	$65.5M	Buy	212,063 +181	+0.1%	+$43.3K	0.45%	56
2020 Q2	$44.5M	Buy	+211,882	New	+$47.2M	0.36%	58

Other funds holding GBIO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Farallon Capital Management's GBIO Position: Q1 2023 in Review

Farallon Capital Management sold out of Generation Bio (GBIO) in Q1 2023, closing a stake of 124,938 shares — an estimated $4.91M sold.

Farallon Capital Management first reported a position in GBIO in Q2 2020 and held it in 11 quarters. The position peaked at $94.2M in Q2 2021. 83 funds tracked by Wall St. Rank hold GBIO as of Q1 2023.

Farallon Capital Management reported no remaining Generation Bio position as of Q1 2023 after selling out during the quarter.
Farallon Capital Management sold 124,938 Generation Bio shares in Q1 2023, an estimated $4.91M.
Farallon Capital Management first reported a position in Generation Bio in Q2 2020 and held it in 11 quarters.
Farallon Capital Management's Generation Bio position peaked at $94.2M in Q2 2021.
83 funds tracked by Wall St. Rank held Generation Bio as of Q1 2023.

Based on Farallon Capital Management's 13F filing for Q1 2023, filed 15 May 2023.